All sponsors

Arrowhead Pharmaceuticals $ARWR

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-34
RECRUITING6
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO29%

Delay Index: of 7 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Arrowhead Pharmaceuticals on the live radar map → 📅 $ARWR readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
ARO-ALK7
NCT06937203
P1/2RecruitingObesity; Diabetes Mellitus, Type 21502027-02 (-7 mo)
ARO-MAPT-SC
NCT07221344
P1/2RecruitingAlzheimer Disease; Tauopathies1602027-06
ARO-DIMERPA
NCT07223658
P1/2RecruitingHyperlipidemia; Mixed782027-07
zodasiran Injection
NCT07037771
P3Active, not recruitingHomozygous Familial Hypercholesterolemia702027-08-20
ARO-INHBE
NCT06700538
P1/2Active, not recruitingObesity1902027-10-15 (+21 mo)
ARO-RAGE
NCT07241546
P2RecruitingAsthma362027-12
SHASTA-10
NCT06822790
P3Active, not recruitingHypertriglyceridemia7102028-07
SPRUCE
NCT07473843
P3RecruitingHomozygous Familial Hypercholesterolemia102028-07
SHASTA-5
NCT06880770
P3RecruitingSevere Hypertriglyceridemia2882029-03 (+12 mo)
ARO-INHBE
NCT07859813
P2Not yet recruitingMetabolic Dysfunction-Associated Steatohepatitis2522029-10